April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Potent Cleavage-Potentiated Gram Negative and Positive Bactericidal Activity of Lacritin Nucleates a Synergistic Defense Mechanism
Author Affiliations & Notes
  • R. L. McKown
    Integrated Science & Technology, James Madison University, Harrisonburg, Virginia
  • E. V. Coleman
    Integrated Science & Technology, James Madison University, Harrisonburg, Virginia
  • A. M. Deleault
    Integrated Science & Technology, James Madison University, Harrisonburg, Virginia
  • R. W. Raab
    Integrated Science & Technology, James Madison University, Harrisonburg, Virginia
  • G. W. Laurie
    Cell Biology, University of Virginia, Charlottesville, Virginia
  • Footnotes
    Commercial Relationships  R.L. McKown, EyeRx Research Inc., F; Office of Tech Transfer, JMU and UVA Patent, P; E.V. Coleman, None; A.M. Deleault, None; R.W. Raab, Office of Tech Transfer, JMU and UVA Patent, P; EyeRx Research Inc., F; G.W. Laurie, EyeRx Research Inc., C; UVa Patent Foundation and Office of Tech Transfer, JMU, P.
  • Footnotes
    Support  NIH RO1 EY013143 and NIH RO1 EY0 18222 (RLM, EVC, GWL). NIH R42 EY015376 (RLM, EVC, RWR). This research was supported by grant funding from Virginia’s Commonwealth Health Research Board (RLM, EVC).
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 4181. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. L. McKown, E. V. Coleman, A. M. Deleault, R. W. Raab, G. W. Laurie; Potent Cleavage-Potentiated Gram Negative and Positive Bactericidal Activity of Lacritin Nucleates a Synergistic Defense Mechanism. Invest. Ophthalmol. Vis. Sci. 2010;51(13):4181.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Lacritin is a 119 amino acid prosecretory mitogen found in tears that stimulates basal tearing in rabbits and promotes human corneal epithelial cell proliferation with a biphasic 1-10 nM dose optimum. Lacritin shows slight sequence alignment with the C-terminus of dermcidin, an important sweat antibiotic. Deletion mutants of lacritin containing C-terminal sequences are antimicrobial against E. coli in the uM range. The human antimicrobial proteins dermcidin and cathelicidin (LL-37) are cleavage-activated by host proteases. Here we ask whether lacritin also displays cleavage dependent antibiotic activity and by what mechanism.

Methods: : Lacritin deletion mutants were generated, expressed in E. coli, and then purified by chitin and DEAE chromatography. A colony forming unit assay was used to assess antimicrobial activity. Bacterial membrane permeabilization was analyzed with the impermeable dye Sytox Green and mammalian membrane permeabilization with the hemolysis assay. Lacritin with supernatants from bacterial cultures were monitored by Western bloting with lacritin C-terminal or N-terminal specific antibodies.

Results: : The deletion mutant N-65, but not intact lacritin is bactericidal against Staphylococcus epidermidis, and Pseudomonas aeruginosa at physiological conditions. The mechanism of bactericidal activity involves rapid membrane permeabilization. No lysis of red blood cells is detected under equivalent conditions, suggesting the involvement of a bacterial surface protein. Incubation of lacritin with bacterial supernatants generated a fragment that is recognized by the C-terminal specific antibody but not the N-terminal specific antibody. A synergistic bactericidal effect is observed when N-65 is combined with human lysozyme.

Conclusions: : We propose that bacteria-dependent cleavage of lacritin releases a potent gram negative and positive bactericidal activity that functions under physiological conditions in a synergistic mechanism with other antimicrobial factors found in human tear film.

Keywords: cornea: tears/tear film/dry eye • lacrimal gland • antibiotics/antifungals/antiparasitics 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×